with samples from healthy individuals, the goal being to fi nd common genetic variations associated with the disease. The problem is that the results so far have not lived up to the promise. Critics point out that although hundreds of single-nucleotide polymorphisms (SNPs) have been found to be associated with one or another disease, the magnitude of risk associated with a SNP is small in most cases. Finding them has not led to rapid drug development or a meaningful improvement in the ability to predict risk. And critics contend that continuing to spend vast amounts of money on these studies is not likely to change that picture, which refl ects the genetics and biology of complex diseases.
GWAS defenders acknowledge that the approach was initially oversold with promises that it would personalize medicine in N E W S the near future, but they insist that genomewide association studies are providing valuable information about biological pathways involved in diseases, including cancer. The key to evaluating the approach, they say, is using a narrower lens and asking about its value in specifi c contexts-and recognizing that much work remains.
There are three main reasons to do these studies, according to Stephen J. Chanock, M.D., chief of the translational genomics laboratory at the National Cancer Institute in Bethesda, Md. The fi rst is discovery of regions that were not previously known to be associated with a disease or human trait; the second is predicting outcomes or response to therapy; and the third is direct-to-consumer clinical and public health applications.
"Domain one has been wildly successful," Chanock continued. "In domain two, we are starting to scratch the surface. Domain three is where people like myself are extremely worried about the overly-aggressive marketing or pushing of these tests, without all of the rigor we would expect. These tests could be transformative but they are not there yet."
Looking only at Chanock's fi rst domain, identifying new loci associated with disease, John P. Ioannidis, M.D., Ph.D. , comes to a similar conclusion. "I think we have been pretty successful actually," said Ioannidis, who leads genetic epidemiology research at Tuft University's Center for Genetic Epidemiology and Modeling in Boston and the University of Ioannina School of Medicine in Greece. That is, GWAS studies have probably been more successful than earlier genetic epidemiology studies "when almost everything that was being discovered could not be replicated in subsequent studies," he said. Ioannidis estimated that GWAS studies have identifi ed about 400 high-quality associations with complex diseases, including up to 100 with cancer. These associations tend to have stronger statistical support than other kinds of genetic epidemiology studies, he said.
Data from genomewide association studies may also provide insight into the etiology of diseases that have been otherwise impenetrable, said Richard S. Houlston, M.D., Ph.D., at the Institute of Cancer Research in the United Kingdom. For example, his research group reported last year that they had uncovered six genetic loci that are associated with chronic lymphocytic leukemia. "It is a common leukemia, associated with massively increased familial risk, but until recently we knew nothing about environmental or genetic risk factors at all," Houlston said. "So we've moved from nothing to something, and that is a critical step in the process." However, translating those initial observations into practice-changing treatments or risk prediction algorithms is more diffi cult. For example, data from two genomewide association studies have shown that a particular genetic locus on chromosome 10 was associated with an increased risk of prostate cancer. In May, Chanock and colleagues reported that the genetic polymorphism uncovered in those studies resides in a gene called MSMB and that the gene variant associated with disease alters how the MSMB protein binds to an important transcription factor in the cell.
"That is what is really hard," Chanock said. "It took a bunch of postdocs 2 years to get that one paper together to try and begin to explain why that signal is associated with prostate cancer. And that still doesn't change patient care or disease prevention strategies." Yet that is the type of detailed molecular information required if one wants to develop targeted therapies based on the gene changes found in genome-wide association studies.
If on the other hand, one wants to develop an algorithm to predict an individual's risk for a given disease, the key challenge is that the polymorphisms uncovered by these studies account for only a very small percentage of the risk in most diseases. To illustrate the point, Hakon Hakonarson, M.D., Ph.D., director of the Center for Applied Genomics at The Children's Hospital of Philadelphia, points to type II diabetes in which more than a dozen gene loci are known to be associated with an increased risk of disease but altogether account for only about 5% of the total risk. Trying to predict who will get the disease based on that very limited risk information would be akin to fl ipping one coin and using the result to predict how 19 other coins would land if they were fl ipped. "There is no way of doing that," Hakonarson said. "We have very poor prediction for diseases where we haven't captured more than a small percentage of risk -and that is true for most of the complex diseases today."
Similarly, a recent study looked at seven SNPs associated with breast cancer, adding them to existing risk factors used in the Breast Cancer Risk Assessment Tool (BCRAT). Mitchell Gail, M.D., Ph.D., at NCI found that the seven SNPs provided only a slight improvement in the accuracy of the tool (J. Natl. Cancer Inst. 2009;101: 959 -963).
Two Possible Strategies
Hakonarson remains convinced that risk prediction based on GWAS fi ndings will be possible in the future but that more variants need to be identifi ed. He points to two possible strategies to move in that direction. In the fi rst, he suggests that increasing the size of genomewide association studies-including using more patients and healthy participants-would enable scientists to uncover variants that have even smaller effects than the variants already identifi ed. Although no one single variant would improve prediction, if all of them were used together, they might account for a substantial amount of risk and thus improve individual risk prediction.
The other approach is to start looking for variants that are rare in the human population but have a bigger effect on disease. "Rare variants are much more likely to be more highly penetrant and therefore constitute more of the risk," Hakonarson said. "So if you do have one, then you are at substantially greater risk of disease." Unfortunately, the microarrays used in genome-wide association studies currently are not designed to test rare variants. He expects, however, that as more individual genomes are sequenced and more variants are assembled, array companies will start to design microarray chips to test them. 
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Not everyone, however, is convinced that the prediction problem will be so easily overcome. Ioannidis points out that accumulating many small-effect variants may allow scientists to predict individual risk for those people whose genome carries lots of "bad" variants and thus are at one end of the risk spectrum or whose genome carries lots of "good" variants and are at the other as the end. But that approach is unlikely to do much for most people who fall in between those extremes.
As for the likelihood of fi nding rare alleles that individually account for a larger proportion of total risk, Ioannidis agrees that the possibility exists, but that it is unclear how many of these will be found. "It may be that some interesting stuff is hiding in the more rare variability, but this is more of a speculation now than knowledge," he said. "What we do know is that when we try to expand coverage to more rare variants or other types of variability, such as copy number or structural variants, it is going to be even more diffi cult in terms of statistical approaches to get the same level of robust support as we get for the common variants that we have targeted today."
Even if the variants can be found that account for a substantial proportion of risk, researchers will need to test their predictive value in prospective clinical trials before they can be used in the clinic regularly. And that raises another challenge in Chanock's view. Many of the high-quality studies and associated tissue collections that have been assembled over the past 20 years have already been used in genome-wide association studies. In breast and prostate cancer, for example, he estimates that 75% of the high-quality sample collections have already been used in these studies. That means few collections are available for replicating initial observations or learning how best to use them clinically.
"What we need looking forward are studies that will let us follow up and refi ne the observations, to get us to the endpoints to be able to say, 'Yes, these are the single nucleotide polymorphisms in breast cancer that are really important when considering whether a 40 year old woman should go to every-2-year mammograms or every year, or whatever, ' " Chanock said.
Now that the day-to-day realities of research have eclipsed some of the initial hyperbole about genomewide association studies, all of the experts interviewed agree that the next steps are not going to be entirely straightforward. "We still have to exploit the maximal utility of this technology," Ioannidis said. "But I think we can say this is not really easy … it is going to be one step at a time."
And though the discovery of particular associations may still make headlines, Houlston emphasized that they are only the start. "Genome-wide association studies are a means to an end, not an end in themselves," he said. "That is the point."
